Inhaled therapies in patients with moderate COPD in clinical practice: current thinking

References

• CohenJSMilesMCDonohueJFOharJADual therapy strategies for COPD: the scientific rationale for LAMA + LABAInt J Chron Obstruct Pulmon Dis20161178579727143870
   PubMed Web of Science ®Google Scholar
• LopezADShibuyaKRaoCChronic obstructive pulmonary disease: current burden and future projectionsEur Respir J20062739741216452599
   PubMed Web of Science ®Google Scholar
• PauwelsRABuistASCalverleyPMJenkinsCRHurdSSGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summaryAm J Respir Crit Care Med20011631256127611316667
   PubMedGoogle Scholar
• European Respiratory SocietyEuropean Lung White BookHuddersfield, UKERS2003
   Google Scholar
• MathersCDLoncarDProjections of global mortality and burden of disease from 2002 to 2030PLoS Med20063e44217132052
   PubMed Web of Science ®Google Scholar
• World Health OrganizationThe top 10 causes of death2017 Available from: http://www.who.int/mediacentre/factsheets/fs310/enAccessed October 31, 2017
   Google Scholar
• BuistASMcBurnieMAVollmerWMInternational variation in the prevalence of COPD (the BOLD study): a population-based prevalence studyLancet200737074175017765523
   PubMed Web of Science ®Google Scholar
• RaherisonCGirodetPOEpidemiology of COPDEur Respir Rev20091821322120956146
   PubMedGoogle Scholar
• LamprechtBMcBurnieMAVollmerWMCOPD in never smokers: results from the population-based Burden of Obstructive Lung Disease studyChest201113975276320884729
   PubMed Web of Science ®Google Scholar
• RocheNSmallMBroomfieldSHigginsVPollardRReal world COPD: association of morning symptoms with clinical and patient reported outcomesCOPD20131067968624127914
   PubMedGoogle Scholar
• KanervistoMPaavilainenEHeikkiläJFamily dynamics in families of severe COPD patientsJ Clin Nurs20081614981505
   Web of Science ®Google Scholar
• CoultasDBMapelDGagnonRLydickEThe health impact of undiagnosed airflow obstruction in a national sample of United States adultsAm J Respir Crit Care Med200116437237711500335
   PubMed Web of Science ®Google Scholar
• O’DonnellDEMaltaisFPorszaszJThe continuum of physiological impairment during treadmill walking in patients with mild-to-moderate COPD: patient characterization phase of a randomized clinical trialPLoS One20149e9657424788342
   PubMed Web of Science ®Google Scholar
• HanninkJDvan HelvoortHADekhuijzenPNHeijdraYFDynamic hyperinflation during daily activities: does COPD global initiative for chronic obstructive lung disease stage matter?Chest20101371116112119952059
   PubMed Web of Science ®Google Scholar
• WatzHWaschkiBMeyerTMagnussenHPhysical activity in patients with COPDEur Respir J20093326227219010994
   PubMed Web of Science ®Google Scholar
• WaschkiBKirstenAMHolzHDisease progression and changes in physical activity in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med201519229530626020495
   PubMed Web of Science ®Google Scholar
• AgustiACalverleyPMCelliBCharacterisation of COPD heterogeneity in the ECLIPSE cohortRespir Res20101112220831787
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoASusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med20103631128113820843247
   PubMed Web of Science ®Google Scholar
• PavordIDJonesPWBurgelPRRabeKFExacerbations of COPDInt J Chron Obstruct Pulmon Dis201611213026937187
   PubMed Web of Science ®Google Scholar
• ManninoDMBuistASPettyTLEnrightPLReddSCLung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up studyThorax20035838839312728157
   PubMed Web of Science ®Google Scholar
• Ekberg-AronssonMPehrssonKNilssonJANilssonPMLöfdahlCGMortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitisRespir Res200569816120227
   PubMed Web of Science ®Google Scholar
• ZbozinkovaZBarczykATkacovaRPOPE study: rationale and methodology of a study to phenotype patients with COPD in Central and Eastern EuropeInt J Chron Obstruct Pulmon Dis20161161162227042048
   PubMed Web of Science ®Google Scholar
• ToljamoTHamariASotkasiiraMNieminenPClinical characteristics of COPD syndrome: a 6-year follow-up study of adult smokersAnn Med20154739940526178878
   PubMed Web of Science ®Google Scholar
• LangePCelliBAgustíALung-function trajectories leading to chronic obstructive pulmonary diseaseN Engl J Med201537311112226154786
   PubMed Web of Science ®Google Scholar
• SvanesCSunyerJPlanaEEarly life origins of chronic obstructive pulmonary diseaseThorax201065142019729360
   PubMed Web of Science ®Google Scholar
• MinasMHatzoglouCKaretsiECOPD prevalence and the differences between newly and previously diagnosed COPD patients in a spirometry programPrim Care Respir J20101936337020532466
   PubMedGoogle Scholar
• GhattasCDaiAGemmelDJAwadMHOver diagnosis of chronic obstructive pulmonary disease in an underserved patient populationInt J Chron Obstruct Pulmon Dis2013854554924348030
   PubMed Web of Science ®Google Scholar
• LindbergABergARönmarkELarssonLGLundbäckBPrevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smokingRespir Med200610026427215975774
   PubMed Web of Science ®Google Scholar
• WaltersJAHansenEMudgePJohnsDPWaltersEHWood-BakerRBarriers to the use of spirometry in general practiceAust Fam Physician20053420120315799676
   PubMedGoogle Scholar
• WaltersJAHansenECWaltersEHWood-BakerRUnder-diagnosis of chronic obstructive pulmonary disease: a qualitative study in primary careRespir Med200810273874318222684
   PubMed Web of Science ®Google Scholar
• MapelDWDalalAABlanchetteCMPetersenHFergusonGTSeverity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claimsInt J Chron Obstruct Pulmon Dis2011657358122135490
   PubMed Web of Science ®Google Scholar
• DransfieldMTKunisakiKMStrandMJAcute exacerbations and lung function loss in smokers with and without COPDAm J Respir Crit Care Med201719532433027556408
   PubMed Web of Science ®Google Scholar
• KimSJLeeJParkJSAge-related annual decline of lung function in patients with COPDInt J Chron Obstruct Pulmon Dis201611516026766907
   PubMed Web of Science ®Google Scholar
• CelliBRDecramerMAsijeeGMKupasKTashkinDPEffects of tiotropium in patients with COPD with low or high risk of exacerbations: a post-hoc analysis from the 4-year UPLIFT trialChronic Obstr Pulm Dis2015212213028848836
   PubMedGoogle Scholar
• FergusonGTFležarMKornSEfficacy of tiotropium + olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysisAdv Ther20153252353626112656
   PubMed Web of Science ®Google Scholar
• CelliBDecramerMKestenSMortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200918094895519729663
   PubMed Web of Science ®Google Scholar
• AnthonisenNRLessons from the Lung Health StudyProc Am Thorac Soc2004114314516113427
   PubMedGoogle Scholar
• ShavelleRMPaculdoDRKushSJManninoDMStraussDJLife expectancy and years of life lost in chronic obstructive pulmonary disease: findings from the NHANES III follow-up studyInt J Chron Obstruct Pulmon Dis2009413714819436692
   PubMedGoogle Scholar
• MateraMGPageCPCazzolaMNovel bronchodilators for the treatment of chronic obstructive pulmonary diseaseTrends Pharm Sci20113249550621683458
   PubMed Web of Science ®Google Scholar
• EjioforSTurnerAMPharmacotherapies for COPDClin Med Insights Circ Respir Pulm Med20137173423700381
   PubMedGoogle Scholar
• CazzolaMCalzettaLMateraMGβ2-Adrenoceptor agonists: current and future directionBr J Pharmacol201116341721232045
   PubMed Web of Science ®Google Scholar
• MeursHDekkersBGJMaarsinghHHalaykoAJZaagsmaJGosensRMuscarinic receptors on airway mesenchymal cells: novel findings for an ancient targetPulm Pharmacol Ther20132614515522842340
   PubMed Web of Science ®Google Scholar
• DalePRCerneckaHSchmidtMThe pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder diseaseCurr Opin Pharmacol201416314224682092
   PubMed Web of Science ®Google Scholar
• DecramerMCelliBKestenSLystigTMehraSTashkinDPEffect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trialLancet20093741171117819716598
   PubMed Web of Science ®Google Scholar
• CasaburiRMaltaisFPorszaszJEffects of tiotropium on hyperinflation and treadmill exercise tolerance in mild to moderate chronic obstructive pulmonary diseaseAnn Am Thorac Soc2014111351136125289942
   PubMedGoogle Scholar
• JenkinsCRJonesPWCalverleyPMEfficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH studyRespir Res2009105919566934
   PubMed Web of Science ®Google Scholar
• TashkinDPFergusonGTCombination bronchodilator therapy in the management of chronic pulmonary diseaseRespir Res2013144923651244
   PubMed Web of Science ®Google Scholar
• BeehKMDeromEEchave-SustaetaJThe lung function profile of once-daily tiotropium and olodaterol via Respimat is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler (ENERGITO study)Int J Chron Obstruct Pulmon Dis20161119320526893551
   PubMed Web of Science ®Google Scholar
• ZhouYZhongNSLiXTiotropium in early-stage chronic obstructive pulmonary diseaseN Engl J Med201737792393528877027
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med20072235677578917314337
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J20154596997925573406
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med20163742222223427181606
   PubMed Web of Science ®Google Scholar
• ZhengJZhongNNewlandsAChurchAGohAHEfficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled studyInt J Chron Obstruct Pulmon Dis2015101753176726366068
   PubMed Web of Science ®Google Scholar
• BatemanEDChapmanKRSinghDAclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multi-center, randomised studies (ACLIFORM and AUGMENT)Respir Res2015169226233481
   PubMed Web of Science ®Google Scholar
• SinghDFergusonGTBolitschekJTiotropium + olodaterol shows clinically meaningful improvements in quality of lifeRespir Med20151091312131926320402
   PubMed Web of Science ®Google Scholar
• BuhlRAbrahamsRGrönkeLKorduckiLFlezarMFergusonGTTiotropium plus olodaterol fixed-dose combination therapy provides lung function benefits when compared with tiotropium alone, irrespective of prior treatment with a long-acting bronchodilator: post hoc analyses of two 1-year studiesAm J Respir Crit Care Med2015191A5755
   Web of Science ®Google Scholar
• FergusonGTPizzichiniEFlezarMGrönkeLKorduckiLThe fixed dose combination of tiotropium + olodaterol has a rapid onset of action in patients with COPDEur Respir J201546A2957
   Web of Science ®Google Scholar
• BeehKMWestermanJKirstenAMThe 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary diseasePulm Pharmacol Ther201532535925956072
   PubMed Web of Science ®Google Scholar
• CazzolaMMcNeeWMartinezFJOutcomes for COPD pharmacological trials: from lung function to biomarkersEur Respir J20083141646918238951
   PubMed Web of Science ®Google Scholar
• MiravitllesMPriceDRabeKFSchmidtHMetzdorfNCelliBComorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis20151054956425834416
   PubMed Web of Science ®Google Scholar
• KernDMDavisJWilliamsSAComparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database studyRespir Res2015165225899176
   PubMed Web of Science ®Google Scholar
• DonohueJFWorsleySZhuCQHardakerLChurchAImprovements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbationsRespir Med201510987088126006754
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J2013421484149423722616
   PubMed Web of Science ®Google Scholar
• OfirDLavenezianaPWebbKAMechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200817762262918006885
   PubMed Web of Science ®Google Scholar
• TroostersTSciurbaFBattagliaSPhysical inactivity in patients with COPD, a controlled multi-center pilot studyRespir Med20101041005101120167463
   PubMed Web of Science ®Google Scholar
• WaschkiBKirstenAHolzOPhysical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort studyChest201114033134221273294
   PubMed Web of Science ®Google Scholar
• Garcia-AymerichJLangePBenetMRegular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort studyThorax20066177277816738033
   PubMed Web of Science ®Google Scholar
• AnderssonMSlindeFGrönbergAMPhysical activity level and its clinical correlates in chronic obstructive pulmonary disease: a cross-sectional studyRespir Res20131412824237876
   PubMed Web of Science ®Google Scholar
• HillKGardinerPACavalheriVPhysical activity and sedentary behaviour: applying lessons to chronic obstructive pulmonary diseaseIntern Med J20154547448225164319
   PubMed Web of Science ®Google Scholar
• ReardonJZLareauSCZuWallackRFunctional status and quality of life in chronic obstructive pulmonary diseaseAm J Med2006119S32S3716563940
   PubMed Web of Science ®Google Scholar
• LacasseYMartinSLassersonTJGoldsteinRSMeta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease: a Cochrane systematic reviewEura Medicophys20074347548518084170
   PubMedGoogle Scholar
• RiesALBauldoffGSCarlinBWPulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelinesChest20071314S42S17494825
   PubMed Web of Science ®Google Scholar
• SantusPRadovanovicDBalzanoGImprovements in lung diffusion capacity following pulmonary rehabilitation in COPD with and without ventilation inhomogeneityRespiration20169229530727598467
   PubMed Web of Science ®Google Scholar
• CasaburiRKukafkaDCooperCBImprovement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPDChest200512780981715764761
   PubMed Web of Science ®Google Scholar
• MaltaisFIturriJBKirstenAEffects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPDThorax201469A186A187
   Web of Science ®Google Scholar
• BeehKMKornSBeierJQVA149 once daily improves exercise tolerance and lung function in patients with moderate to severe COPD: the BRIGHT studyThorax201267A147
   Web of Science ®Google Scholar
• TroostersTBourbeauJMaltaisFEnhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study designBMJ Open20166e010106
   Web of Science ®Google Scholar
• O’DonnellDECasaburiRFrithPEffects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPDEur Respir J201749160134828424359
   PubMed Web of Science ®Google Scholar
• BeehKMBurgelPRFranssenFMHow do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease?Am J Respir Crit Care Med201719613914927922741
   PubMed Web of Science ®Google Scholar
• QaseemAWiltTJWeinbergerSEDiagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory SocietyAnn Intern Med201115517919121810710
   PubMed Web of Science ®Google Scholar
• KoblizekVChlumskyJZindrVChronic obstructive pulmonary disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society – a novel phenotypic approach to COPD with patient-oriented careBiomed Pap Med Fac Univ Palacky Olomouc Czech Repub201315718920123733084
   PubMed Web of Science ®Google Scholar
• RussiEWKarrerWBrutscheMDiagnosis and management of chronic obstructive pulmonary disease: the Swiss guidelinesRespiration20138516017423406723
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med20113641093110321428765
   PubMed Web of Science ®Google Scholar
• DecramerMLChapmanKRDahlROnce-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group studyLancet Respir Med2013152453324461613
   PubMed Web of Science ®Google Scholar
• VestboJAndersonJBrookRDStudy to understand mortality and morbidity in COPD (SUMMIT)Eur Respir J201546OA3476
   Web of Science ®Google Scholar
• PecchiariMMSantusPRadovanovicDD’AngeloEGThe acute effects of long acting bronchodilators on small airways detected in COPD patients by single breath N2 test and lung P-V curveJ Appl Physiol (1985) Epub201783
   Web of Science ®Google Scholar
• TagayaEYagiOSatoAEffect of tiotropium on mucus hypersecretion and airway clearance in patients with COPDPulm Pharmacol Ther201639818427350218
   PubMed Web of Science ®Google Scholar
• JehnMSchmidt-TrucksässAMeyerAAssociation of daily physical activity volume and intensity with COPD severityRespir Med20111051846185221803556
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMSeemungalTAThe role of bronchodilator treatment in the prevention of exacerbations of COPDEur Respir J2012401545155422835613
   PubMed Web of Science ®Google Scholar
• SantusPRadovanovicDDi MarcoSEffect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trialInt J Chron Obstruct Pulmon Dis2015101917192326392766
   PubMed Web of Science ®Google Scholar
• HawkinsNMViraniSCeconiCHeart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health servicesEur Heart J2013342795280323832490
   PubMed Web of Science ®Google Scholar
• CelliBDecramerMLeimerICardiovascular safety of tiotropium in patients with COPDChest2010137203019592475
   PubMed Web of Science ®Google Scholar
• RottenkolberMRottenkolberDFischerRInhaled β2-agonists/muscarinic antagonists and acute myocardial infarction in COPD patientsRespir Med20141081075109024950946
   PubMed Web of Science ®Google Scholar
• RabeKFTimmerWSagkriotisAVielKComparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPDChest200813425526218403672
   PubMed Web of Science ®Google Scholar
• VogelmeierCBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomized, double-blind, parallel group studyLancet Respir Med20131516024321804
   PubMed Web of Science ®Google Scholar
• DonohueJFHananiaNAMakeBOne-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPDChest201414661531154225451347
   PubMed Web of Science ®Google Scholar
• VogelmeierCPaggiaroPLDorcaGEfficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD studyEur Respir J2016481030103927492833
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of COPDBethesda (MD)GOLD2017
   Google Scholar
• KoblizekVMilenkovicBBarczykAPhenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE studyEur Respir J201749160144628495687
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of COPDBethesda (MD)GOLD2016
   Google Scholar
• TudoricNKoblizekVMiravitllesMGOLD 2017 on the way to a phenotypic approach? Analysis from the phenotypes of COPD in Central and Eastern Europe (POPE) cohortEur Respir J201749160251828446560
   PubMed Web of Science ®Google Scholar
• PascoeSJLipsonDALocantoreNA phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocolEur Respir J20164832033027418551
   PubMed Web of Science ®Google Scholar
• KozmaCMParisALPlauschinatCAComparison of resource by COPD patients on inhaled therapies with long-acting bronchodilators: a database studyBMC Pulm Med2011116122192866
   PubMed Web of Science ®Google Scholar
• van BovenJKocksJWPostmaMJCost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropiumolodaterol for patients with COPD in the NetherlandsInt J Chron Obstruct Pulmon Dis2016112191220127703341
   PubMed Web of Science ®Google Scholar
• Boehringer IngelheimComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5 µg in reducing moderate to severe exacerbations in patients with severe to very severe chronic obstructive pulmonary disease Available from: https://clinicaltrials.gov/ct2/show/NCT2296138. NLM identifier: NCT2296138Accessed October 31, 2017
   Google Scholar
• MiravitllesMVogelmeierCRocheNA review of national guidelines for management of COPD in EuropeEur Respir J20164762563726797035
   PubMed Web of Science ®Google Scholar
• BarnesPJCorticosteroid resistance in patients with asthma and chronic obstructive pulmonary diseaseJ Allergy Clin Immunol201313163664523360759
   PubMed Web of Science ®Google Scholar
• PauwelsRALofdahlCGLaitinenLALong-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smokingN Engl J Med19993401948195310379018
   PubMed Web of Science ®Google Scholar
• VestboJSorensenTLangePLong-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trialLancet19993531819182310359405
   PubMed Web of Science ®Google Scholar
• Lung Health Study Research GroupEffect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary diseaseN Engl J Med20003431902190911136260
   PubMed Web of Science ®Google Scholar
• BurgePSCalverleyPMJonesPWRandomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ20003201297130310807619
   PubMed Web of Science ®Google Scholar
• AaronSDFergussonDMarksGBCounting, analysing and reporting exacerbations of COPD in randomised controlled trialsThorax20086312212817702790
   PubMed Web of Science ®Google Scholar
• La VecchiaCFabbriLMPrevention of death in COPDN Engl J Med200735622112212
   PubMed Web of Science ®Google Scholar
• SuissaSErnstPVandemheenKLAaronSDMethodological issues in therapeutic trials of COPDEur Respir J20083192793318216056
   PubMed Web of Science ®Google Scholar
• SpencerSKarnerCCatesCJEvansDJInhaled corticosteroids versus long-acting β2-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev2011CD0070033
   Google Scholar
• VestboJLeatherDBakerlyNDEffectiveness of fluticasone furoate-vilanterol for COPD in clinical practiceN Engl J Med20163751253126027593504
   PubMed Web of Science ®Google Scholar
• DavisKJLandisSHOhYMContinuing to Confront COPD International Physician Survey: physician knowledge and application of COPD management guidelines in 12 countriesInt J Chron Obstruct Pulmon Dis201410395525565799
   PubMed Web of Science ®Google Scholar
• BrusselleGProceDGruffydd-JonesKThe inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UKInt J Chron Obstruct Pulmon Dis2015102207221726527869
   PubMed Web of Science ®Google Scholar
• PriceDBrusselleGWestGManagement of COPD in the UK primary-care setting: an analysis of real-life prescribing patternsInt J Chron Obstruct Pulmon Dis2014988990425210450
   PubMed Web of Science ®Google Scholar
• BarrechegurenMMonteagudoMFerrerJTreatment patterns in COPD patients newly diagnosed in primary care: a population-based studyRespir Med2016111475326758585
   PubMed Web of Science ®Google Scholar
• PerezXWisniveskyJPLurslurchachaiLBarriers to adherence to COPD guidelines among primary care providersRespir Med201210637438122000501
   PubMed Web of Science ®Google Scholar
• SalinasGDWilliamsonJCKalhanRBarriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physiciansInt J Chron Obstruct Pulmon Dis2011617117921468169
   PubMed Web of Science ®Google Scholar
• BorosPWMartusewicz-BorosMMReversibility of airway obstruction vs bronchodilatation: do we speak the same language?COPD2012921321522475111
   PubMedGoogle Scholar
• DecramerMBartschPPauwelsRManagement of COPD according to guidelines: a national survey among Belgian physiciansMonaldo Arch Chest Dis2003596280
   PubMedGoogle Scholar
• MiravittlesMAndreuIRomeroYDifficulties in differential diagnosis of COPD and asthma in primary careBr J Gen Pract201262e68e7522520766
   PubMed Web of Science ®Google Scholar
• GlaabTBanikNRutshmannOTWenckerMNational survey of guideline compliant COPD management among pulmonologists and primary care physiciansCOPD2006314114817240616
   PubMedGoogle Scholar
• LucasAESmeenkFWSmeeleIJvan SchayckCPOvertreatment with inhaled corticosteroids and diagnostic problems in primary care patients, an exploratory studyFam Pract200825869118304973
   PubMed Web of Science ®Google Scholar
• ErnstPSaadNSuissaSInhaled corticosteroids in COPD: the clinical evidenceEur Respir J20154552553725537556
   PubMed Web of Science ®Google Scholar
• FlynnRWMacDonaldTMHapcaAQuantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysisRespir Res20141514125407604
   PubMed Web of Science ®Google Scholar
• PriceDYawnBBrusselleGRossiARisk-to-benefit ratio of inhaled corticosteroids in patients with COPDPrim Care Respir J2013229210023135217
   PubMedGoogle Scholar
• BabuKSKastelikJAMorjariaJBInhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspectiveBr J Clin Pharmacol20147828230025099256
   PubMed Web of Science ®Google Scholar
• LeeMCLeeCHChienSCInhaled corticosteroids increase the risk of pneumonia in patients with chronic obstructive pulmonary disease: a nationwide cohort studyMedicine (Baltimore)201594e172326496284
   PubMed Web of Science ®Google Scholar
• DiSantostefanoRLSampsonTLeHVHindsDDavisKJBakerlyNDRisk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort studyPLoS One20149e9714924878543
   PubMed Web of Science ®Google Scholar
• CrimCCalverleyPMAndersonJAPneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study resultsEur Respir J20093464164719443528
   PubMed Web of Science ®Google Scholar
• FesticEBansalVGuptaEScanlonPDAssociation of inhaled corticosteroids with incident pneumonia and mortality in COPD patients: systematic review and meta-analysisCOPD20161331232626645797
   PubMedGoogle Scholar
• ErnstPGonzalezAVBrassardPInhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumoniaAm J Respir Crit Care Med200717616216617400730
   PubMed Web of Science ®Google Scholar
• SuissaSCoulombeJErnstPDiscontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumoniaChest20151481177118326110239
   PubMed Web of Science ®Google Scholar
• MiravittlesMSoler-CataluñaJJCalleMSorianoJBTreatment of COPD by clinical phenotypes: putting old evidence into clinical practiceEur Respir J2013411252125623060631
   PubMed Web of Science ®Google Scholar
• HardinMSilvermanEBarrRGThe clinical features of the overlap between COPD and asthmaRespir Res20111212721951550
   PubMed Web of Science ®Google Scholar
• Global Initiative for AsthmaGlobal Strategy for Asthma Management and PreventionBethesda (MD)GINA2017
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease, Global Initiative for AsthmaDiagnosis of diseases of chronic airflow limitation: asthma, COPD, and asthma-COPD overlap syndrome (ACOS)2015 Available from: http://goldcopd.org/asthma-copd-asthma-copd-overlap-syndromeAccessed October 31, 2017
   Google Scholar
• LimHSChoiSMLeeJResponsiveness to inhaled corticosteroid treatment in patients with asthma-chronic obstructive pulmonary disease overlap syndromeAnn Allergy Asthma Immunol201411365265725280465
   PubMed Web of Science ®Google Scholar
• PostmaDSRabeKFThe asthma-COPD overlap syndromeN Engl J Med20153731241124926398072
   PubMed Web of Science ®Google Scholar
• BarnesPJTherapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromesJ Allergy Clin Immunol201513653154526343937
   PubMed Web of Science ®Google Scholar
• D’UrzoADonohueJFKardosPA re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary diseaseExpert Opin Pharmacother2015161845186026194213
   PubMed Web of Science ®Google Scholar
• SiddiquiSHGuasconiAVestboJBlood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med201519252352526051430
   PubMed Web of Science ®Google Scholar
• PascoeSLocantoreNDransfieldMTBlood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trialsLancet Respir Med2015343544225878028
   PubMed Web of Science ®Google Scholar
• WatzHTetzlaffKWoutersEBlood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trialLancet Respir Med2016439039827066739
   PubMed Web of Science ®Google Scholar
• BarnesNCSharmaRLettisSCalverleyPMBlood eosinophils as a marker of response to inhaled corticosteroids in COPDEur Respir J2016471374138226917606
   PubMed Web of Science ®Google Scholar
• JaradNAWedzichaJABurgePSCalverleyPMAn observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary diseaseRespir Med19999316116610464871
   PubMed Web of Science ®Google Scholar
• van der ValkPMonninkhofEvan der PalenJEffect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE studyAm J Respir Crit Care Med20021661358136312406823
   PubMed Web of Science ®Google Scholar
• ChoudhuryABDawsonCMKilvingtonHEWithdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trialRespir Res200789318162137
   PubMed Web of Science ®Google Scholar
• WoutersEFPostmaDSFokkensBWithdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trialThorax20056048048715923248
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med20143711285129425196117
   PubMed Web of Science ®Google Scholar
• YawnBPSuissaSRossiAAppropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawalNPJ Prim Care Respir Med2016261606827684954
   PubMed Web of Science ®Google Scholar
• MagnussenHTetzlaffKBatemanEDLung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPDEur Respir J20164765165426585433
   PubMed Web of Science ®Google Scholar
• CalzettaLMateraMGBraidoFWithdrawal of inhaled corticosteroids in COPD: a meta-analysisPulm Pharmacol Ther20174514815828606478
   PubMed Web of Science ®Google Scholar
• RossiAvan der MolenTdel OlmoRINSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPDEur Respir J2014441548155625359348
   PubMed Web of Science ®Google Scholar
• KaplanAGApplying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practiceInt J Chron Obstruct Pulmon Dis2015102535254826648711
   PubMed Web of Science ®Google Scholar
• MiravitllesMD’UrzoASinghDKoblizekVPharmacological strategies to reduce exacerbation risk in COPD: a narrative reviewRespir Res20161711227613392
   PubMed Web of Science ®Google Scholar